Abstract

1107P Clinical outcomes to checkpoint inhibitors in NRAS mutated metastatic melanoma (MM) compared with wild type BRAF/NRAS: An Italian Melanoma Intergroup (IMI) study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients.
Barbara Silvestri ... Peter Mohr
Journal of Clinical Oncology | VOL. 31
Barbara Silvestri, et. al.Barbara Silvestri ... Peter Mohr
20 May 2013
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
...
Cancers | VOL. 13
, et. al. ...
26 Jan 2021
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)
Milena Casula ... Enrica Teresa Tanda
Diagnostic Pathology | VOL. 15
Milena Casula, et. al.Milena Casula ... Enrica Teresa Tanda
01 Dec 2020
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
Mario Mandalà ... Barbara Merelli
European Journal of Cancer | VOL. 137
Mario Mandalà, et. al.Mario Mandalà ... Barbara Merelli
30 Jul 2020
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
H Li ... E Song
Annals of Oncology | VOL. -
H Li, et. al.H Li ... E Song
01 May 2024
View more papers